Scancell Holdings (GB:SCLP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
In a strategic move, Scancell Holdings has appointed Dr. Phil L’Huillier as the new CEO, bringing his extensive experience in the pharmaceutical industry to bolster the company’s efforts in pioneering cancer immunotherapies. This leadership change aims to leverage Scancell’s innovative platforms, ImmunoBody® and Moditope®, to advance their clinical trials and potentially enhance investor value. Former CEO Professor Lindy Durrant will remain as Chief Scientific Officer, continuing to support the company’s scientific endeavors.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
